- Home
- PRMB vs AXSM Comparison
PRMB vs AXSM Comparison
Compare PRMB & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRMB | AXSM |
|---|---|---|
| Founded | 1955 | 2012 |
| Country | United States | United States |
| Employees | 12600 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.6B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PRMB | AXSM |
|---|---|---|
| Price | $20.17 | $228.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 17 |
| Target Price | $24.00 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 2.8M | 681.1K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.34 | $57.24 |
| Revenue Next Year | $3.56 | $55.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.36 | $96.09 |
| 52 Week High | $33.70 | $217.00 |
Technical Indicators
Market Signals| Indicator | PRMB | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 81.45 |
| Support Level | $17.90 | $148.87 |
| Resistance Level | $22.96 | N/A |
| Average True Range (ATR) | 0.71 | 10.02 |
| MACD | 0.01 | 3.46 |
| Stochastic Oscillator | 45.01 | 88.71 |
Price Performance
Historical ComparisonAbout PRMB Primo Brands Corporation
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.